The U.S. FDA has granted orphan drug designation to CS1, Cereno Scientific’s lead therapy candidate for treating pulmonary arterial hypertension (PAH).| Pulmonary Hypertension News
The post Marvel Biosciences to File for Orphan Drug Designation with the U.S. FDA for MB-204 as a Treatment for Rett Syndrome appeared first on Marvel Biosciences.| Marvel Biosciences